Michael A Schwarzschild

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Targeting adenosine A2A receptors in Parkinson's disease
    Michael A Schwarzschild
    MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, MA 02129, USA
    Trends Neurosci 29:647-54. 2006
  2. ncbi Adenosine A2A antagonists as neurotherapeutics: crossing the bridge
    Michael A Schwarzschild
    MassGeneral Institute for Neurodegenerative Disease, Boston, USA
    Prog Neurobiol 83:261-2. 2007
  3. ncbi Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease
    Michael A Schwarzschild
    Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA
    Neurology 61:S55-61. 2003
  4. ncbi Caffeinated clues and the promise of adenosine A(2A) antagonists in PD
    Michael A Schwarzschild
    Department of Neurology, Massachusetts General Hospital, Boston, USA
    Neurology 58:1154-60. 2002
  5. ncbi Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease
    Jiang Fan Chen
    Molecular Neurobiology Laboratory, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02118, USA
    Neurology 61:S74-81. 2003
  6. ncbi Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice
    Danqing Xiao
    Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA
    J Neurosci 26:13548-55. 2006
  7. ncbi Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice
    Kui Xu
    Department of Neurology, Massachusetts General Hospital, 02129, Charlestown, MA, USA
    Neurosci Lett 322:13-6. 2002
  8. ncbi Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice
    Anil Kachroo
    MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02129, USA
    J Neurosci 25:10414-9. 2005
  9. ncbi A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization
    Elena Bastia
    Molecular Neurobiology Laboratory, Department of Neurology, MassGeneral Institute for Neurodegenerative Disease and Harvard Medical School, Boston, MA 02129, USA
    Neuropsychopharmacology 30:891-900. 2005
  10. ncbi Plasma urate and Parkinson's disease in women
    Eilis J O'Reilly
    Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA
    Am J Epidemiol 172:666-70. 2010

Research Grants

  1. Targeting Adenosine A2A Receptors in Parkinson's Disease
    Michael Schwarzschild; Fiscal Year: 2006
  2. Translational Foundation of Adenosine Antagonist Use for Dyskinesias
    Michael Schwarzschild; Fiscal Year: 2007
  3. Translational Foundation of Adenosine Antagonist Use for Dyskinesias
    Michael Schwarzschild; Fiscal Year: 2007
  4. Translational Foundation of Adenosine Antagonist Use for Dyskinesias
    Michael A Schwarzschild; Fiscal Year: 2010
  5. A2A Adenosine Receptors in Psychostimulant Sensitization
    Michael Schwarzschild; Fiscal Year: 2005
  6. Novel Neuroprotection by Caffeine in Parkinson's Disease
    Michael Schwarzschild; Fiscal Year: 2005
  7. Translating A2A Receptor Biology into Novel PD Therapy
    Michael Schwarzschild; Fiscal Year: 2002
  8. Translational Foundation of Adenosine Antagonist Use for Dyskinesias
    Michael Schwarzschild; Fiscal Year: 2009

Detail Information

Publications76

  1. ncbi Targeting adenosine A2A receptors in Parkinson's disease
    Michael A Schwarzschild
    MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, MA 02129, USA
    Trends Neurosci 29:647-54. 2006
    ..Thus, we review here a prime example of translational neuroscience, through which antagonism of A2A receptors has now entered the arena of clinical trials with realistic prospects for advancing PD therapeutics...
  2. ncbi Adenosine A2A antagonists as neurotherapeutics: crossing the bridge
    Michael A Schwarzschild
    MassGeneral Institute for Neurodegenerative Disease, Boston, USA
    Prog Neurobiol 83:261-2. 2007
  3. ncbi Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease
    Michael A Schwarzschild
    Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA
    Neurology 61:S55-61. 2003
    ....
  4. ncbi Caffeinated clues and the promise of adenosine A(2A) antagonists in PD
    Michael A Schwarzschild
    Department of Neurology, Massachusetts General Hospital, Boston, USA
    Neurology 58:1154-60. 2002
    ..Now, with the prospect of a neuroprotective bonus, the novel therapeutic potential of A(2A) antagonists appears all the more promising just as they are entering clinical trials for PD...
  5. ncbi Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease
    Jiang Fan Chen
    Molecular Neurobiology Laboratory, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02118, USA
    Neurology 61:S74-81. 2003
    ..Potential presynaptic, postsynaptic (cellular), and trans-synaptic (network) mechanisms are discussed...
  6. ncbi Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice
    Danqing Xiao
    Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA
    J Neurosci 26:13548-55. 2006
    ....
  7. ncbi Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice
    Kui Xu
    Department of Neurology, Massachusetts General Hospital, 02129, Charlestown, MA, USA
    Neurosci Lett 322:13-6. 2002
    ..These data raise the possibility that caffeine may induce neuroprotection and locomotion by distinct mechanisms...
  8. ncbi Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice
    Anil Kachroo
    MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02129, USA
    J Neurosci 25:10414-9. 2005
    ..These data also strengthen a rationale for pursuing a combinational drug strategy for enhancing the antiparkinsonian effects of A2A and mGlu5 antagonists...
  9. ncbi A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization
    Elena Bastia
    Molecular Neurobiology Laboratory, Department of Neurology, MassGeneral Institute for Neurodegenerative Disease and Harvard Medical School, Boston, MA 02129, USA
    Neuropsychopharmacology 30:891-900. 2005
    ..Thus activation of brain A(2A)Rs plays a critical role in developing augmented psychomotor responses to repeated psychostimulant exposure...
  10. ncbi Plasma urate and Parkinson's disease in women
    Eilis J O'Reilly
    Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA
    Am J Epidemiol 172:666-70. 2010
    ..Unlike in men, these findings do not support the hypothesis that urate is strongly associated with lower rates of Parkinson's disease among women...
  11. ncbi Obesity, diabetes, and risk of Parkinson's disease
    Natalia Palacios
    Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA
    Mov Disord 26:2253-9. 2011
    ..The results did not differ significantly by gender. Our results do not provide evidence for a relationship between body mass index, weight change, waist circumference, or baseline diabetes and risk of Parkinson's disease...
  12. ncbi Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration
    Anil Kachroo
    MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA
    Exp Neurol 223:657-61. 2010
    ..Caffeine at 20mg/kg significantly reduced TH+ neuron loss (to 85% of the respective control). The results demonstrate the neuroprotective potential of caffeine in a chronic pesticide exposure model of model of PD...
  13. ncbi 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism
    Jiang Fan Chen
    Department of Neurology, Molecular Neurobiology Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02129, USA
    J Biol Chem 277:36040-4. 2002
    ..Together, these data indicate that CSC possesses dual actions of MAO-B inhibition and A(2A) receptor antagonism, a unique combination suggesting a new class of compounds with the potential for enhanced neuroprotective properties...
  14. ncbi Genetic and pharmacological inactivation of adenosine A2A receptor reveals an Egr-2-mediated transcriptional regulatory network in the mouse striatum
    Liqun Yu
    Department of Neurology, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Physiol Genomics 23:89-102. 2005
    ..Taken together, these results strongly support the existence of an Egr-2-directed transcriptional regulatory network controlled by striatal A2ARs...
  15. ncbi Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice
    Liqun Yu
    Department of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston, 02114, USA
    Neurosci Lett 393:31-5. 2006
    ....
  16. ncbi Inactivation of adenosine A2A receptors selectively attenuates amphetamine-induced behavioral sensitization
    Jiang Fan Chen
    Molecular Neurobiology Laboratory, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA
    Neuropsychopharmacology 28:1086-95. 2003
    ....
  17. ncbi Deletion of adenosine A? or A(?A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease
    Danqing Xiao
    MassGeneral Institute for Neurolodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA
    Brain Res 1367:310-8. 2011
    ..Our findings raise the possibility that A? or A(?A) receptors blockade might also confer a disease-modifying benefit of reduced risk of disabling LID, whereas the effect of their combined inactivation is less clear...
  18. ncbi Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32
    Anthone W Dunah
    Department of Neurology, Massachusetts General Hospital, Center for Aging, Genetics, and Neurodegeneration, Charlestown, MA 02129, USA
    Mol Pharmacol 65:121-9. 2004
    ..Strategies that prevent NMDA receptor subcellular redistribution through inhibition of Fyn kinase may prove useful in the treatment of Parkinson's disease...
  19. ncbi Recreational physical activity and risk of Parkinson's disease
    Evan L Thacker
    Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA
    Mov Disord 23:69-74. 2008
    ..Our results may be explained either by a reduction in PD risk through moderate to vigorous activity, or by decreased baseline recreational activity due to preclinical PD...
  20. ncbi Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease
    Kui Xu
    Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA
    J Neurosci 26:535-41. 2006
    ....
  21. ncbi Prenatal and early life factors and risk of Parkinson's disease
    Hannah Gardener
    Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
    Mov Disord 25:1560-7. 2010
    ..Left-handedness was associated with a 62% increased risk of PD in women but not in men. Further investigation of the relation between prenatal, perinatal, or neonatal factors and PD in other study populations is suggested...
  22. ncbi Calcium channel blocker use and risk of Parkinson's disease
    Kelly Claire Simon
    Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Mov Disord 25:1818-22. 2010
    ..18, 95% CI: 0.73-1.92), frequency of use or duration of use of CCBs and PD risk was observed (P > 0.2 for all). These findings do not support a role for CCBs in providing neuroprotection against development of PD...
  23. ncbi Restless legs syndrome and Parkinson's disease in men
    Xiang Gao
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, Massachusetts, USA
    Mov Disord 25:2654-7. 2010
    ..In conclusion, men with RLS are more likely to have concurrent PD. Prospective studies are warranted to clarify the temporal relationship between RLS and PD...
  24. ncbi Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease
    Nikolaus R McFarland
    MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129 4404, USA
    J Neuropathol Exp Neurol 68:515-24. 2009
    ..Further study is needed to clarify the effects of these S129 mutants and alpha-synuclein phosphorylation in mammalian systems...
  25. ncbi Obesity and restless legs syndrome in men and women
    Xiang Gao
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
    Neurology 72:1255-61. 2009
    ..We therefore examined whether individuals who are obese have an increased risk of RLS in two ongoing US cohorts, the Nurses' Health Study II and the Health Professional Follow-up Study...
  26. ncbi Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage
    J Stephen Fink
    Department of Neurology, Boston University School of Medicine, MA 02118, USA
    J Neurochem 88:538-44. 2004
    ....
  27. ncbi Urate as a predictor of the rate of clinical decline in Parkinson disease
    Alberto Ascherio
    Departments of Nutrition and Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
    Arch Neurol 66:1460-8. 2009
    ..The risk of Parkinson disease (PD) and its rate of progression may decline with increasing concentration of blood urate, a major antioxidant...
  28. ncbi Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease
    Kelly Claire Simon
    Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA
    Mov Disord 24:1359-65. 2009
    ..The use of postmenopausal hormone use may interact with other risk factors, but findings are preliminary and need confirmation in other populations...
  29. ncbi Folate intake and risk of Parkinson's disease
    Honglei Chen
    Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA
    Am J Epidemiol 160:368-75. 2004
    ..Intake of vitamin B(6) or vitamin B(12) also was not related to the risk of Parkinson's disease. The current study does not support the hypothesis that higher intake of folate or related B vitamins lowers the risk of Parkinson's disease...
  30. ncbi Obesity and the risk of Parkinson's disease
    Honglei Chen
    Department of Nutrition, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA
    Am J Epidemiol 159:547-55. 2004
    ..03) for waist-to-hip ratio. The results do not support a role of overall obesity in PD pathogenesis; however, central obesity may be associated with higher PD risk among never smokers, and this finding merits further investigation...
  31. ncbi Genetic determinants of hair color and Parkinson's disease risk
    Xiang Gao
    Department of Nutrition, Harvard University School of Public Health, Boston, MA, USA
    Ann Neurol 65:76-82. 2009
    ....
  32. ncbi Restless legs syndrome and erectile dysfunction
    Xiang Gao
    Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Sleep 33:75-9. 2010
    ..Dopaminergic hypofunction in the central nervous system may contribute to restless legs syndrome (RLS) and erectile dysfunction (ED). We therefore examined whether men with RLS have higher prevalences of ED...
  33. ncbi Smoking and Parkinson's disease: using parental smoking as a proxy to explore causality
    Eilis J O'Reilly
    Department of Epidemiology and Nutrition, Harvard School of Public Health, Boston, MA 02215, USA
    Am J Epidemiol 169:678-82. 2009
    ..If the inverse association between smoking and Parkinson's disease were due to confounding by an environmental factor or were the result of reverse causation, it is unlikely that parental smoking would predict Parkinson's disease...
  34. ncbi Pesticide exposure and risk for Parkinson's disease
    Alberto Ascherio
    Department of Nutrition, Harvard School of Public Health, Boston, MA, USA
    Ann Neurol 60:197-203. 2006
    ..Chronic, low-dose exposure to pesticides is suspected to increase the risk for Parkinson's disease (PD), but data are inconclusive...
  35. ncbi DARPP chocolate: a caffeinated morsel of striatal signaling
    Elena Bastia
    Center for Aging, Genetics and Neurodegeneration, Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA
    Sci STKE 2003:PE2. 2003
    ..They highlight the role of postsynaptic A2A receptor blockade, but leave open the possibility that antagonism of presynaptic or postsynaptic A1 receptors also contributes to DARPP-32-dependent psychomotor stimulation by caffeine...
  36. ncbi Diet, urate, and Parkinson's disease risk in men
    Xiang Gao
    Department of Nutrition, School of Public Health, Harvard University, Boston, MA 02115, USA
    Am J Epidemiol 167:831-8. 2008
    ..These potential benefits, however, should be weighed against expected adverse effects on risk of gout and other chronic diseases...
  37. ncbi Plasma urate and progression of mild cognitive impairment
    Michael C Irizarry
    Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
    Neurodegener Dis 6:23-8. 2009
    ..Impaired antioxidant defenses are implicated in neurodegenerative disease. The plasma levels of urate, a water-soluble antioxidant, are reduced in Alzheimer's disease (AD)...
  38. ncbi Use of ibuprofen and risk of Parkinson disease
    Xiang Gao
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, 181 Longwood Ave, Boston, MA 02115, USA
    Neurology 76:863-9. 2011
    ..Use of nonsteroidal anti-inflammatory drugs (NSAID) in general, and possibly ibuprofen in particular, has been shown to be related to lower PD risk in previous epidemiologic studies...
  39. ncbi Alcohol consumption and the incidence of Parkinson's disease
    Miguel A Hernán
    Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
    Ann Neurol 54:170-5. 2003
    ..7 (0.5-0.9) for one to three drinks of beer per month, and 0.7 (0.5, 0.9) for one or more drinks of beer per week. The risk of PD was similar in individuals who usually consume moderate amounts of alcohol and in abstainers...
  40. ncbi Serum urate and probability of dopaminergic deficit in early "Parkinson's disease"
    Michael A Schwarzschild
    Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Mov Disord 26:1864-8. 2011
    ..The findings support the diagnostic utility of urate in combination with other determinants...
  41. ncbi Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors
    Silva Fredduzzi
    Molecular Neurobiology Laboratory, Massachusetts General Hospital, Boston, Massachusetts 02129, USA
    J Neurosci 22:1054-62. 2002
    ..Furthermore, they raise the possibility that the maladaptive dyskinetic responses to chronic l-DOPA treatment in Parkinson's disease may be attenuated by A(2A) receptor inactivation...
  42. ncbi Erectile function and risk of Parkinson's disease
    Xiang Gao
    Department of Nutrition, Harvard University School of Public Health, Boston, MA 02115, USA
    Am J Epidemiol 166:1446-50. 2007
    ..In conclusion, in this retrospective analysis in a large cohort of men, the authors observed that erectile dysfunction was associated with a higher risk of developing Parkinson's disease...
  43. ncbi Perceived imbalance and risk of Parkinson's disease
    Xiang Gao
    Department of Nutrition, Harvard University School of Public Health, Boston, Massachusetts 02115, USA
    Mov Disord 23:613-6. 2008
    ..This result suggests that the imbalance may in some cases be an early sign of PD, and may represent the onset of motor symptoms although they have not been clinically recognized...
  44. ncbi Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease
    Honglei Chen
    Department of Nutrition, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA
    Arch Neurol 60:1059-64. 2003
    ..Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce dopaminergic neuron degeneration in animal models of Parkinson disease (PD). However, no epidemiological data have been available on NSAID use and the risk of PD...
  45. ncbi Serum urate as a predictor of clinical and radiographic progression in Parkinson disease
    Michael A Schwarzschild
    MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, USA
    Arch Neurol 65:716-23. 2008
    ..To determine whether concentration of serum urate, a purine metabolite and potent antioxidant that has been linked to a reduced risk of Parkinson disease (PD), predicts prognosis in PD...
  46. ncbi Characterization of genomic organization of the adenosine A2A receptor gene by molecular and bioinformatics analyses
    Liqun Yu
    Department of Neurology, Boston University School of Medicine, 715 Albany Street, Boston, MA 02118, USA
    Brain Res 1000:156-73. 2004
    ..This raises the possibility of generating multiple tissue-specific A(2A)R mRNA species by alternative promoters with varying regulatory susceptibility...
  47. ncbi Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease
    Yolanda D Black
    Department of Neurology, Massachusetts General Hospital, Charlestown, MA 02129, USA
    Neurosci Lett 486:161-5. 2010
    ..Our findings substantiate the key role of mGluR5 receptors in animal models of PD, strengthening the rationale for the development of mGluR5 antagonists for their neuroprotective, as well as symptomatic, benefit...
  48. ncbi A prospective study of bowel movement frequency and risk of Parkinson's disease
    Xiang Gao
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
    Am J Epidemiol 174:546-51. 2011
    ..In conclusion, infrequent bowel movements may antedate the onset of cardinal motor symptoms of Parkinson's disease and may contribute to the identification of populations with higher than average Parkinson's disease risk...
  49. ncbi Telomere length and risk of Parkinson's disease
    Hao Wang
    Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Mov Disord 23:302-5. 2008
    ..the highest quartile 0.33; 95% confidence interval: 0.12-0.90). Our results suggest that, contrary to telomere attrition observed in several aging-related diseases, shorter telomeres are not associated with an increased risk of PD...
  50. ncbi Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice
    Teresa Gomez-Isla
    Department of Neurology, University of Minnesota, Minneapolis, MN 55455, USA
    Neurobiol Aging 24:245-58. 2003
    ..Thus, high expression of mutant human alpha-synuclein resulted in a progressive motor and widespread CNS gliotic phenotype independent of dopaminergic dysfunction in the Tg5093 line...
  51. ncbi Prospective study of dietary pattern and risk of Parkinson disease
    Xiang Gao
    Department of Nutrition, Harvard School of Public Health, Cambridge, MA 02115, USA
    Am J Clin Nutr 86:1486-94. 2007
    ..Several studies have shown associations between Parkinson Disease (PD) risk and individual foods and nutrients with inconsistent results...
  52. ncbi Molecular markers of early Parkinson's disease based on gene expression in blood
    Clemens R Scherzer
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 104:955-60. 2007
    ..59 +/- 0.05) than in controls (0.96 +/- 0.09) (P = 0.002) in two independent populations. Thus, gene expression signals measured in blood can facilitate the development of biomarkers for PD...
  53. ncbi Prospective study of statin use and risk of Parkinson disease
    Xiang Gao
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
    Arch Neurol 69:380-4. 2012
    ..To prospectively examine whether use of statins is associated with altered risk of Parkinson disease (PD)...
  54. ncbi Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis
    Sara Cipriani
    Massachusetts General Hospital, 114 16th Street, Boston, MA 02129, USA
    Biomark Med 4:701-12. 2010
    ..In this article we review the convergent biological, epidemiological and clinical data that identify urate as a promising biomarker of the risk, diagnosis and prognosis of PD...
  55. ncbi Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience
    Robert A Hauser
    Department of Neurology, University of South Florida and Tampa General Healthcare, Tampa, Florida 33606, USA
    Drugs Aging 22:471-82. 2005
    ..Additional studies are necessary to evaluate the benefit of istradefylline as monotherapy in early disease, its effect on the development of dyskinesia, and its effect on disease progression...
  56. ncbi Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?
    Albert Y Hung
    Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Curr Opin Neurol 20:477-83. 2007
    ..To summarize recently published results of neuroprotection trials for Parkinson's disease, and discuss them in the context of evolving concepts in clinical study design and animal models...
  57. ncbi Prospective study of phobic anxiety and risk of Parkinson's disease
    Marc G Weisskopf
    Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Mov Disord 18:646-51. 2003
    ..Our results suggest that anxiety is a risk factor for PD. Whether this association is causal or the result of shared underlying biology remains a question...
  58. ncbi Adenosine A2A receptor gene disruption protects in an ?-synuclein model of Parkinson's disease
    Anil Kachroo
    MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Boston, USA
    Ann Neurol 71:278-82. 2012
    ..Together with prior studies the present findings indirectly support the neuroprotective potential of caffeine and more specific A(2A) antagonists...
  59. ncbi Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists
    Jacobus P Petzer
    Department of Chemistry, Virginia Tech, Blacksburg, VA 24061-0212, USA
    Bioorg Med Chem 11:1299-310. 2003
    ....
  60. ncbi Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
    Honglei Chen
    Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA
    Ann Neurol 58:963-7. 2005
    ..03). No association was found between the use of aspirin, other nonsteroidal antiinflammatory drugs, or acetaminophen and PD risk. The results suggest that ibuprofen use may delay or prevent the onset of PD...
  61. ncbi Adenosine A1 and A2A receptor regulation of protein phosphatase 2A in the murine heart
    Eugene I Tikh
    Department of Physiology, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
    J Cell Physiol 216:83-90. 2008
    ..These data show that A(2A)R and A(1)R regulate PP2A activity, thus suggesting an important mechanism for modulating myocardial contractility...
  62. ncbi Survival of Parkinson's disease patients in a large prospective cohort of male health professionals
    Honglei Chen
    Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA
    Mov Disord 21:1002-7. 2006
    ..However, smoking seems to impose little additional risk among PD patients in this large cohort of health professionals...
  63. ncbi Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine
    Zhi Li Huang
    Department of Molecular Behavioral Biology, Osaka Bioscience Institute, Osaka 565 0874, Japan
    Nat Neurosci 8:858-9. 2005
    ..Thus, caffeine-induced wakefulness depends on adenosine A2A receptors...
  64. ncbi Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin
    Samuel Joseph Leibovich
    Department of Cell Biology and Molecular Medicine, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, New Jersey 07103, USA
    Am J Pathol 160:2231-44. 2002
    ....
  65. ncbi A prospective study of night shift work, sleep duration, and risk of Parkinson's disease
    Honglei Chen
    Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA
    Am J Epidemiol 163:726-30. 2006
    ..Conversely, habitual longer sleep duration may be an earlier marker of Parkinson's disease. Because of the novelty and the exploratory nature of these findings, confirmation is needed...
  66. ncbi Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis
    Edwin S L Chan
    Division of Clinical Pharmacology, Department of Medicine, New York University School of Medicine, New York, NY 10016, USA
    Br J Pharmacol 148:1144-55. 2006
    ..6. These results demonstrate that hepatic adenosine A(2A) receptors play an active role in the pathogenesis of hepatic fibrosis, and suggest a novel therapeutic target in the treatment and prevention of hepatic cirrhosis...
  67. ncbi Novel pharmacological targets for the treatment of Parkinson's disease
    Anthony H V Schapira
    University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, Rowland Hill Street, London NW3 2PF, UK
    Nat Rev Drug Discov 5:845-54. 2006
    ....
  68. ncbi Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists
    Neal Castagnoli
    Department of Chemistry, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061 0212, USA
    Neurology 61:S62-8. 2003
    ..The results raise the possibility that a single structure may offer the combined benefits of two pharmacologic strategies, each with symptomatic and potential neuroprotective benefits, for the management of PD...
  69. ncbi Consumption of dairy products and risk of Parkinson's disease
    Honglei Chen
    Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA
    Am J Epidemiol 165:998-1006. 2007
    ..8, 2.1). These data suggest that dairy consumption may increase the risk of Parkinson's disease, particularly in men. More studies are needed to further examine these findings and to explore underlying mechanisms...
  70. ncbi Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications
    Micaela Morelli
    University of Cagliari, Department of Toxicology, Via Ospedale 72, 09124 Cagliari, Italy
    Prog Neurobiol 83:293-309. 2007
    ..Finally, concluding remarks are made on post-mortem human brains and on the translation of adenosine A2A receptor antagonists in the treatment of PD...
  71. ncbi Peripheral inflammatory biomarkers and risk of Parkinson's disease
    Honglei Chen
    Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA
    Am J Epidemiol 167:90-5. 2008
    ..However, this finding should be interpreted with caution because of the small sample size and the lack of associations with other biomarkers of inflammation...
  72. ncbi Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors
    M Carmen Montesinos
    Department of Medicine, New York University School of Medicine, New York, New York, USA
    Am J Pathol 160:2009-18. 2002
    ..Thus, targeting the adenosine A(2A) receptor is a novel approach to promoting wound healing and angiogenesis in normal individuals and those suffering from chronic wounds...
  73. ncbi Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia
    Josep Saura
    Department of Pharmacology and Toxicology, IIBB, CSIC, IDIBAPS, Barcelona, Spain
    J Neurochem 95:919-29. 2005
    ....
  74. ncbi Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells
    Yuan Ji Day
    Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, Virginia 22908, USA
    J Clin Invest 112:883-91. 2003
    ..We conclude that protection from renal IRI by A2AR agonists or endogenous adenosine requires activation of receptors expressed on BM-derived cells...
  75. ncbi Sleep regulation in adenosine A2A receptor-deficient mice
    Yoshihiro Urade
    Department of Molecular Behavioral Biology, Osaka Bioscience Institute, Osaka, Japan
    Neurology 61:S94-6. 2003

Research Grants20

  1. Targeting Adenosine A2A Receptors in Parkinson's Disease
    Michael Schwarzschild; Fiscal Year: 2006
    ..Thus this timely conference is designed to catalyze the development of A2A antagonists as a novel multi-faceted treatment strategy for Parkinson's disease and related CMS disorders. ..
  2. Translational Foundation of Adenosine Antagonist Use for Dyskinesias
    Michael Schwarzschild; Fiscal Year: 2007
    ....
  3. Translational Foundation of Adenosine Antagonist Use for Dyskinesias
    Michael Schwarzschild; Fiscal Year: 2007
    ..abstract_text> ..
  4. Translational Foundation of Adenosine Antagonist Use for Dyskinesias
    Michael A Schwarzschild; Fiscal Year: 2010
    ....
  5. A2A Adenosine Receptors in Psychostimulant Sensitization
    Michael Schwarzschild; Fiscal Year: 2005
    ..clarify the role of A2A receptors in psychostimulant-induced addictive behaviors, and thus may encourage the development of novel, specific strategies for treating psychostimulant abuse and related addiction disorders ..
  6. Novel Neuroprotection by Caffeine in Parkinson's Disease
    Michael Schwarzschild; Fiscal Year: 2005
    ....
  7. Translating A2A Receptor Biology into Novel PD Therapy
    Michael Schwarzschild; Fiscal Year: 2002
    ..Thus, this timely conference stands to serve as a catalyst for developing A2A antagonists as a novel multi-faceted treatment strategy for Parkinson's disease. ..
  8. Translational Foundation of Adenosine Antagonist Use for Dyskinesias
    Michael Schwarzschild; Fiscal Year: 2009
    ....